← All trials
NCT07215884
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Oct 14, 2025
- Last posted
- Oct 14, 2025
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoOfficial
- National Institute on Deafness and Other Communication Disorders (NIDCD)Collaborator
- University of WashingtonCollaborator
- University of WashingtonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.